Suppression of Gonadotropins and Estradiol in Premenopausal Women by Oral Administration of the Nonpeptide Gonadotropin-Releasing Hormone Antagonist Elagolix | Zendy

R. Scott Struthers | Zendy; Andrew Nicholls | Zendy; John S. Grundy | Zendy; Takung Chen | Zendy; Roland Jimenez | Zendy; Samuel S.C. Yen | Zendy; Haig Bozigian | Zendy

Open Access

Suppression of Gonadotropins and Estradiol in Premenopausal Women by Oral Administration of the Nonpeptide Gonadotropin-Releasing Hormone Antagonist Elagolix

Author(s) -

R. Scott Struthers,

Andrew Nicholls,

John S. Grundy,

Takung Chen,

Roland Jimenez,

Samuel S.C. Yen,

Haig Bozigian

Publication year - 2008

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2008-1695

Subject(s) - medicine , endocrinology , placebo , tolerability , hormone antagonist , pharmacokinetics , oral administration , hormone , antagonist , follicular phase , endocrine system , gonadotropin , gonadotropin releasing hormone antagonist , gonadotropin releasing hormone , luteinizing hormone , adverse effect , receptor , alternative medicine , pathology

Parenteral administration of peptide GnRH analogs is widely employed for treatment of endometriosis and fibroids and in assisted-reproductive therapy protocols. Elagolix is a novel, orally available nonpeptide GnRH antagonist.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research